Total Payments
$69,936
2024 Payments
$4,778
Companies
13
Transactions
78
Medicare Patients
454
Medicare Billing
$44,959
Payment Breakdown by Category
Consulting$48,809 (69.8%)
Other$9,790 (14.0%)
Travel$7,178 (10.3%)
Research$2,644 (3.8%)
Food & Beverage$1,425 (2.0%)
Education$90.25 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $48,809 | 19 | 69.8% |
| Travel and Lodging | $7,178 | 20 | 10.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,200 | 2 | 7.4% |
| Honoraria | $4,590 | 1 | 6.6% |
| Unspecified | $2,644 | 3 | 3.8% |
| Food and Beverage | $1,425 | 29 | 2.0% |
| Education | $90.25 | 4 | 0.1% |
Payments by Type
General
$67,292
75 transactions
Research
$2,644
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $33,101 | 29 | $0 (2022) |
| Strongbridge US INC. | $7,044 | 9 | $0 (2018) |
| Roche Products Limited | $4,622 | 3 | $0 (2021) |
| PFIZER INC. | $4,600 | 2 | $0 (2020) |
| GENZYME CORPORATION | $4,042 | 3 | $0 (2019) |
| PTC Therapeutics, Inc. | $3,628 | 8 | $0 (2018) |
| Biogen, Inc. | $3,408 | 12 | $0 (2019) |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $3,400 | 4 | $0 (2022) |
| Lupin Inc. | $2,438 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,060 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,778 | 3 | Lupin Inc. ($2,438) |
| 2023 | $1,272 | 3 | F. Hoffmann-La Roche AG ($1,244) |
| 2022 | $13,951 | 10 | Sarepta Therapeutics, Inc. ($10,551) |
| 2021 | $3,300 | 1 | Roche Products Limited ($3,300) |
| 2020 | $7,400 | 3 | Sarepta Therapeutics, Inc. ($6,000) |
| 2019 | $13,266 | 11 | Sarepta Therapeutics, Inc. ($7,038) |
| 2018 | $12,968 | 30 | Sarepta Therapeutics, Inc. ($4,519) |
| 2017 | $13,001 | 17 | Strongbridge US INC. ($6,972) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,060.00 | General |
| 12/11/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $280.00 | General |
| 01/26/2024 | Lupin Inc. | — | Consulting Fee | Cash or cash equivalent | $2,437.50 | General |
| 11/27/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Education | In-kind items and services | $28.47 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $930.91 | Research |
| Study: MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with facioscapulohumeral muscular dystrophy (FSHD) | ||||||
| 03/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $312.63 | Research |
| Study: MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with facioscapulohumeral muscular dystrophy (FSHD) | ||||||
| 05/14/2022 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,550.00 | General |
| 05/07/2022 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $1,093.70 | General |
| 05/07/2022 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $507.12 | General |
| 05/07/2022 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $300.00 | General |
| 05/07/2022 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $50.09 | General |
| 05/07/2022 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $50.09 | General |
| 03/14/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 03/14/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 03/14/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 03/02/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/20/2021 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/14/2020 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Genetic Disease | ||||||
| 11/23/2020 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 01/27/2020 | PFIZER INC. | — | — | In-kind items and services | $1,400.00 | Research |
| Study: DMD AND RARE NEUROSCIENCE CLINICAL PUBLICATION PROGRAM | ||||||
| 11/25/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Genetic Disease | ||||||
| 11/09/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Travel and Lodging | In-kind items and services | $558.27 | General |
| Category: Genetic Disease | ||||||
| 11/09/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Travel and Lodging | In-kind items and services | $210.15 | General |
| Category: Genetic Disease | ||||||
| 11/09/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Travel and Lodging | In-kind items and services | $137.50 | General |
| Category: Genetic Disease | ||||||
| 11/09/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Genetic Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DMD AND RARE NEUROSCIENCE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with facioscapulohumeral muscular dystrophy (FSHD) | F. Hoffmann-La Roche AG | $1,244 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 124 | 175 | $32,732 | $12,254 |
| 2022 | 2 | 114 | 160 | $25,768 | $11,297 |
| 2021 | 2 | 110 | 173 | $28,446 | $12,483 |
| 2020 | 1 | 106 | 163 | $25,964 | $8,924 |
Total Patients
454
Total Services
671
Medicare Billing
$44,959
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 91 | 134 | $25,058 | $8,982 | 35.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 22 | $4,318 | $2,125 | 49.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 19 | $3,356 | $1,148 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 96 | 142 | $22,532 | $9,512 | 42.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 18 | $3,236 | $1,785 | 55.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 94 | 157 | $25,798 | $10,779 | 41.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 16 | $2,648 | $1,704 | 64.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 106 | 163 | $25,964 | $8,924 | 34.4% |
About Dr. Jeffrey Statland, MD
Dr. Jeffrey Statland, MD is a Internal Medicine healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578781209.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Statland, MD has received a total of $69,936 in payments from pharmaceutical and medical device companies, with $4,778 received in 2024. These payments were reported across 78 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($48,809).
As a Medicare-enrolled provider, Statland has provided services to 454 Medicare beneficiaries, totaling 671 services with total Medicare billing of $44,959. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology, Neuromuscular Medicine
- Location Kansas City, KS
- Active Since 04/20/2007
- Last Updated 04/28/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1578781209
Products in Payments
- Exondys 51 (Drug) $10,038
- EXONDYS 51 (Drug) $9,512
- KEVEYIS (Drug) $7,044
- Emflaza (Drug) $3,608
- SPINRAZA (Biological) $3,408
- LUMIZYME (Drug) $3,006
- Non-Covered Product (Drug) $1,322
- NO PRODUCT DISCUSSED (Drug) $1,036
- Repatha (Biological) $41.11
- Radicava (Drug) $28.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Kansas City
James O'keefe, Md, MD
Internal Medicine — Payments: $834,178
Internal Medicine $834,178
Shadi Hamdeh, Md, MD
Internal Medicine — Payments: $623,244
Internal Medicine $623,244
Dr. Patrick Moriarty, M.d, M.D
Internal Medicine — Payments: $618,967
Internal Medicine $618,967
Gerald Mancuso, M.d, M.D
Internal Medicine — Payments: $615,894
Internal Medicine $615,894
Dr. Ryan Taylor, M.d, M.D
Internal Medicine — Payments: $512,094
Internal Medicine $512,094
Sanjaya Gupta, Md, MD
Internal Medicine — Payments: $325,155
Internal Medicine $325,155